MYRIAD GENETICS INC. - COMMON STOCK

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

17 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

03 Nov 2022 17:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

01 Nov 2022 08:10:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Third Quarter Financial Results

01 Nov 2022 08:05:01 By Nasdaq GlobeNewswire

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

31 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

26 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

28 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

25 Aug 2022 15:05:00 By Nasdaq GlobeNewswire